呼吸道合胞病毒的预防与治疗进展
摘要
<正>呼吸道合胞病毒(respiratory syncytial virus,RSV)是引起细支气管炎最常见的病原体,不同国家RSV感染率报道不同。本文就国内外近期在RSV感染预防和治疗领域的新进展进行综述。1治疗领域的研究进展1.1气道扩张剂:小气道上皮的急性炎症、大量黏液分泌和支气管痉挛是RSV引起细支气管炎的病理机制。临床表现为喘息。β_2受体激动剂和M受体阻滞剂在临床上是经常被选用的气道扩张剂。大量随机对照试验未能显示疗效的稳定性,同时可伴有心动过速、震颤、血氧饱和度降低等不良反应,美
引文
[1]中华医学会儿科学分会呼吸学组.毛细支气管炎诊断、治疗与预防专家共识(2014年版)[J].中华儿科杂志,2015,53(3):168-170.
[2]Drysdale SB,Green CA,Sande CJ.Best practice in the prevention and management of paediatric respiratory syncytial virus infection[J].Ther Adv Infect Dis,2016,3(2):63-71.
[3]Liu F,Ouyang J,Sharma AN,et al.Leukotriene inhibitors for bronchiolitis in infants and young children[J].Cochrane Database Syst Rev,2015,16(3):CD010636.
[4]中华医学会儿科学分会呼吸学组.白三烯受体拮抗剂在儿童常见呼吸系统疾病中的临床应用专家共识[J].中华实用儿科临床杂志,2016,31(13):973-975.
[5]王浩,尚云晓.雾化吸入药物对毛细支气管炎患儿发作期治疗的机制研究进展[J].国际儿科学杂志,2013,40(5):450-453.
[6]Everard M,Hind D,Ugonna K,et al.Saline in acute bronchiolitis RCT and economic evaluation:hypertonic saline in acute bronchiolitis randomised controlled trial and systematic review[J].Health Technol Assess,2015,19:1130.
[7]Zhang L,Mendoza-Sassi R,Klassen T,et al.Nebulized hypertonic saline for acute bronchiolitis:a systematic review[J].Pediatrics,2015,136:687-701.
[8]李清民.3%及5%氯化钠溶液在毛细支气管炎患儿雾化吸入中的应用效果比较[J].山东医药,2015,55(11):48-50.
[9]陆娇,顾,马卫宁,等.雾化吸入不同浓度高渗盐水治疗中重度毛细支气管炎的疗效和安全性研究[J].中国小儿急救医学,2017,24(6):425-429.
[10]Teunissen J,Hochs AH,Vaessen-Verberne A,et al.The effect of 3%and 6%hypertonic saline in viral bronchiolitis:a randomised controlled trial[J].Eur Respir J,2014,44(4):913-921.
[11]Seliem W,Sultan AM.Heliox delivered by high flow nasal cannula improves oxygenation in infants with respiratory syncytial virus acute bronchiolitis[J].J Pediatr,2018,94(1):56-61.
[12]刘瑞清,张国成,黄可飞,等.重组人干扰素α1b对呼吸道合胞病毒感染小鼠外周血T淋巴细胞亚群及肺组织病理学的影响[J].现代生物医学进展,2013,13(9):1639-1644.
[13]尚云晓,黄英,刘恩梅,等.雾化吸入重组人干扰素α1b治疗小儿急性毛细支气管炎多中心研究[J].中国实用儿科杂志,2014,29(11):840-844.
[14]赵德育,刘红霞,刘峰,等.雾化吸入重组人干扰素α2b治疗小儿毛细支气管炎有效性和安全性的随机对照多中心研究[J].中华实用儿科临床杂志,2016,31(14):1095-1100.
[15]王兵,程婷,卢晨,等.重组人干扰素2b与儿童雾化吸入药物的配伍研究[J].中华妇幼临床医学杂志,2017,13(7):474-481.
[16]Hallak LK,Collins PL,Knudson W,et al.Iduronic acidcontaining glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection[J].Virology,2000,271(2):264-275.
[17]Numata M,Chu HW,Dakhama A,et al.Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection[J].Proc Natl Acad Sci USA,2010,107(1):320-325.
[18]Villafana T,Falloon J,Griffin MP,et al.Passive and active immunization against respiratory syncytial virus for the young and old[J].Expert Rev Vaccines,2017,16:1-13.
[19]Green C,Yeates D,Goldacre A,et al.Admission to hospital for bronchiolitis in England:trends over five decades,geographical variation and association with perinatal characteristics and subsequent asthma[J].Arch Dis Child,2016,101(2):140-146.
[20]Raguz MJ,Brzica J,Grgic I.Palivizumab:the effects of prophylactic immunization on the occurrence of infectionscaused by the respiratory syncytial virus[J].Klin Padiatr,2017,229(5):281-285.
[21]Ramilo O,Lagos R,Sáez-Llorens X,et al.Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness[J].Pediatr Infect Dis J,2014,33:703-709.
[22]Bergin N,Murtagh J,Philip RK.Maternal vaccination as an essential component of life-course immunization and its contribution to preventive neonatology[J].Int J Environ Res Public Health,2018,15(5):E847.
[23]Omer SB.Maternal immunization[J].N Engl J Med,2017,376(13):1256-1267.
[2]Drysdale SB,Green CA,Sande CJ.Best practice in the prevention and management of paediatric respiratory syncytial virus infection[J].Ther Adv Infect Dis,2016,3(2):63-71.
[3]Liu F,Ouyang J,Sharma AN,et al.Leukotriene inhibitors for bronchiolitis in infants and young children[J].Cochrane Database Syst Rev,2015,16(3):CD010636.
[4]中华医学会儿科学分会呼吸学组.白三烯受体拮抗剂在儿童常见呼吸系统疾病中的临床应用专家共识[J].中华实用儿科临床杂志,2016,31(13):973-975.
[5]王浩,尚云晓.雾化吸入药物对毛细支气管炎患儿发作期治疗的机制研究进展[J].国际儿科学杂志,2013,40(5):450-453.
[6]Everard M,Hind D,Ugonna K,et al.Saline in acute bronchiolitis RCT and economic evaluation:hypertonic saline in acute bronchiolitis randomised controlled trial and systematic review[J].Health Technol Assess,2015,19:1130.
[7]Zhang L,Mendoza-Sassi R,Klassen T,et al.Nebulized hypertonic saline for acute bronchiolitis:a systematic review[J].Pediatrics,2015,136:687-701.
[8]李清民.3%及5%氯化钠溶液在毛细支气管炎患儿雾化吸入中的应用效果比较[J].山东医药,2015,55(11):48-50.
[9]陆娇,顾,马卫宁,等.雾化吸入不同浓度高渗盐水治疗中重度毛细支气管炎的疗效和安全性研究[J].中国小儿急救医学,2017,24(6):425-429.
[10]Teunissen J,Hochs AH,Vaessen-Verberne A,et al.The effect of 3%and 6%hypertonic saline in viral bronchiolitis:a randomised controlled trial[J].Eur Respir J,2014,44(4):913-921.
[11]Seliem W,Sultan AM.Heliox delivered by high flow nasal cannula improves oxygenation in infants with respiratory syncytial virus acute bronchiolitis[J].J Pediatr,2018,94(1):56-61.
[12]刘瑞清,张国成,黄可飞,等.重组人干扰素α1b对呼吸道合胞病毒感染小鼠外周血T淋巴细胞亚群及肺组织病理学的影响[J].现代生物医学进展,2013,13(9):1639-1644.
[13]尚云晓,黄英,刘恩梅,等.雾化吸入重组人干扰素α1b治疗小儿急性毛细支气管炎多中心研究[J].中国实用儿科杂志,2014,29(11):840-844.
[14]赵德育,刘红霞,刘峰,等.雾化吸入重组人干扰素α2b治疗小儿毛细支气管炎有效性和安全性的随机对照多中心研究[J].中华实用儿科临床杂志,2016,31(14):1095-1100.
[15]王兵,程婷,卢晨,等.重组人干扰素2b与儿童雾化吸入药物的配伍研究[J].中华妇幼临床医学杂志,2017,13(7):474-481.
[16]Hallak LK,Collins PL,Knudson W,et al.Iduronic acidcontaining glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection[J].Virology,2000,271(2):264-275.
[17]Numata M,Chu HW,Dakhama A,et al.Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection[J].Proc Natl Acad Sci USA,2010,107(1):320-325.
[18]Villafana T,Falloon J,Griffin MP,et al.Passive and active immunization against respiratory syncytial virus for the young and old[J].Expert Rev Vaccines,2017,16:1-13.
[19]Green C,Yeates D,Goldacre A,et al.Admission to hospital for bronchiolitis in England:trends over five decades,geographical variation and association with perinatal characteristics and subsequent asthma[J].Arch Dis Child,2016,101(2):140-146.
[20]Raguz MJ,Brzica J,Grgic I.Palivizumab:the effects of prophylactic immunization on the occurrence of infectionscaused by the respiratory syncytial virus[J].Klin Padiatr,2017,229(5):281-285.
[21]Ramilo O,Lagos R,Sáez-Llorens X,et al.Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness[J].Pediatr Infect Dis J,2014,33:703-709.
[22]Bergin N,Murtagh J,Philip RK.Maternal vaccination as an essential component of life-course immunization and its contribution to preventive neonatology[J].Int J Environ Res Public Health,2018,15(5):E847.
[23]Omer SB.Maternal immunization[J].N Engl J Med,2017,376(13):1256-1267.